person · Reporting owner

Arroyo Santiago

Disclosed activity across 4 companies

Tapewire entity: 84384
SEC CIK: 0001706857

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BICYCLE THERAPEUTICS PLCBCYC · Entity 5993	CHIEF DEVELOPMENT OFFICER	January 02, 2025	January 06, 2025
Fulcrum Therapeutics, Inc.FULC · Entity 5969	Chief Medical Officer	November 07, 2022	November 09, 2022
MARINUS PHARMACEUTICALS, INC.MRNS · Entity 83359	Director	February 04, 2022	February 07, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BICYCLE THERAPEUTICS PLC

Report date January 02, 2025 · Filed January 06, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	69,057	Ending reported balance After 2025-01-02 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-01-02 · Grant · Acquired 35,000 · Balance 74,000 F1: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2: Each RSU represents a contingent right to receive one ordinary share. Row 2 · 2025-01-02 · Sale · Disposed 4,943 · Balance 69,057 F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2035-01-02	Direct	87,000	Reported balance After 2025-01-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-01-02 · Grant · Acquired 87,000 · Balance 87,000 F5: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.

F2: Each RSU represents a contingent right to receive one ordinary share.

F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter.

Fulcrum Therapeutics, Inc.

Report date November 07, 2022 · Filed November 09, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.61 · Expires 2032-11-06	Direct	400,000	Reported balance After 2022-11-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-11-07 · Grant · Acquired 400,000 · Balance 400,000 F1: This option was granted on November 7, 2022 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of November 7, 2022. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on November 7, 2022 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of November 7, 2022. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.

MARINUS PHARMACEUTICALS, INC.

Report date February 04, 2022 · Filed February 07, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,750	Reported balance After 2022-02-04 transaction · row 1 1 source row Row 1 · 2022-02-04 · Grant · Acquired 2,750 · Balance 2,750 F1: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on February 4, 2023, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2032-02-04	Direct	12,375	Reported balance After 2022-02-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-02-04 · Grant · Acquired 12,375 · Balance 12,375 F2: The option vests and becomes exercisable in 12 equal monthly installments beginning on March 4, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on February 4, 2023, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer.

F2: The option vests and becomes exercisable in 12 equal monthly installments beginning on March 4, 2022.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MOMENTA PHARMACEUTICALS INC

Report date October 01, 2020 · Filed October 01, 2020

Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-10-01 transaction · row 1 1 source row Row 1 · 2020-10-01 · Disposition to issuer · Disposed 26 · Balance 0 F1: Includes 26 shares acquired under the Issuer's employee stock purchase plan on September 28, 2020. F2: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-10-01 · Disposition to issuer · Disposed 45,000 · Balance 0 F3: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-01 · Disposition to issuer · Disposed 52,500 · Balance 0 F3: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-01 · Disposition to issuer · Disposed 31,500 · Balance 0 F3: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20	Direct	Reported balance After 2020-10-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-01 · Disposition to issuer · Disposed 23,252 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11	Direct	Reported balance After 2020-10-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-10-01 · Disposition to issuer · Disposed 15,674 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07	Direct	Reported balance After 2020-10-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-10-01 · Disposition to issuer · Disposed 3,137 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20	Direct	Reported balance After 2020-10-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-10-01 · Disposition to issuer · Disposed 36,748 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.76 · Expires 2029-02-11	Direct	Reported balance After 2020-10-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-10-01 · Disposition to issuer · Disposed 73,702 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.87 · Expires 2030-02-07	Direct	Reported balance After 2020-10-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-10-01 · Disposition to issuer · Disposed 101,863 · Balance 0 F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 26 shares acquired under the Issuer's employee stock purchase plan on September 28, 2020.

F2: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.

F3: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.

F4: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 02, 2025 Filed Jan 6, 2025 19:30 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantEmployee Stock Option (right to buy) · Derivative	87,000	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0001415889-25-000926 · form4-01062025_070123.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,000 Underlying: Ordinary Shares · 87,000 shares Expires 2035-01-02 F5 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document
January 02, 2025 Filed Jan 6, 2025 19:30 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	SaleOrdinary Shares	4,943	$14.09	$69,646.87	Disclosure SEC source: 0001415889-25-000926 · form4-01062025_070123.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,057 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 02, 2025 Filed Jan 6, 2025 19:30 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	35,000	$0.00	$0.00	Disclosure SEC source: 0001415889-25-000926 · form4-01062025_070123.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
February 06, 2024 Filed Feb 8, 2024 16:42 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantEmployee Stock Option (right to buy) · Derivative	41,570	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0001415889-24-003009 · form4-02082024_090249.xml · derivative · entry 2 Arroyo Santiago · CIK 0001706857 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,570 Underlying: Ordinary Shares · 41,570 shares Expires 2034-02-06 F3 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document
February 06, 2024 Filed Feb 8, 2024 16:42 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	21,660	$0.00	$0.00	Disclosure SEC source: 0001415889-24-003009 · form4-02082024_090249.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,000 F1 · kind: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
January 02, 2024 Filed Jan 4, 2024 18:29 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantEmployee Stock Option (right to buy) · Derivative	35,430	$0.00 Strike: $18.08	$0.00	Disclosure SEC source: 0001209191-24-000880 · doc4.xml · derivative · entry 2 Arroyo Santiago · CIK 0001706857 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,430 Underlying: Ordinary Shares · 35,430 shares Expires 2034-01-02 F3 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document
January 02, 2024 Filed Jan 4, 2024 18:29 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	17,340	$0.00	$0.00	Disclosure SEC source: 0001209191-24-000880 · doc4.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,340 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
March 31, 2023 Filed Apr 4, 2023 16:12 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantEmployee Stock Option (right to buy) · Derivative	120,000	$0.00 Strike: $21.77	$0.00	Disclosure SEC source: 0001209191-23-022667 · doc4.xml · derivative · entry 1 Arroyo Santiago · CIK 0001706857 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Ordinary Shares · 120,000 shares Expires 2033-03-31 F1 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on the first anniversary of the date of grant and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the individual remaining a service provider of the issuer through each such date. Read SEC document
November 07, 2022 Filed Nov 9, 2022 21:15 UTC	Fulcrum Therapeutics, Inc. FULC · Entity 5969	GrantStock Option (right to buy) · Derivative	400,000	$0.00 Strike: $5.61	$0.00	Disclosure SEC source: 0000899243-22-035434 · doc4.xml · derivative · entry 1 Arroyo Santiago · CIK 0001706857 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-11-06 F1 · derivative.exercise_date: This option was granted on November 7, 2022 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of November 7, 2022. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service. Read SEC document
February 04, 2022 Filed Feb 7, 2022 16:06 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock Option (Right to Buy) · Derivative	12,375	$0.00 Strike: $10.40	$0.00	Disclosure SEC source: 0001104659-22-012777 · tm225605-1_4seq1.xml · derivative · entry 2 Arroyo Santiago · CIK 0001706857 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,375 Underlying: Common Stock · 12,375 shares Expires 2032-02-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on March 4, 2022. Read SEC document
February 04, 2022 Filed Feb 7, 2022 16:06 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantCommon Stock	2,750	$0.00	$0.00	Disclosure SEC source: 0001104659-22-012777 · tm225605-1_4seq1.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on February 4, 2023, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document
July 01, 2021 Filed Jul 2, 2021 06:01 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	GrantStock option (right to buy) · Derivative	33,000	$0.00 Strike: $18.70	$0.00	Disclosure SEC source: 0001104659-21-088488 · tm2121105-3_4seq1.xml · derivative · entry 1 Arroyo Santiago · CIK 0001706857 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: Option to purchase shares of common stock vests in 36 equal monthly installments, commencing on 7/31/2021. Read SEC document
October 01, 2020 Filed Oct 1, 2020 16:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerStock Option (Right to Buy) · Derivative	101,863	Not disclosed Strike: $31.87	Not disclosed	Disclosure SEC source: 0001179110-20-010051 · edgar.xml · derivative · entry 10 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,863 shares Expires 2030-02-07 F4 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F4 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document
October 01, 2020 Filed Oct 1, 2020 16:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerStock Option (Right to Buy) · Derivative	73,702	Not disclosed Strike: $12.76	Not disclosed	Disclosure SEC source: 0001179110-20-010051 · edgar.xml · derivative · entry 9 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,702 shares Expires 2029-02-11 F4 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F4 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document
October 01, 2020 Filed Oct 1, 2020 16:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerStock Option (Right to Buy) · Derivative	36,748	Not disclosed Strike: $17.20	Not disclosed	Disclosure SEC source: 0001179110-20-010051 · edgar.xml · derivative · entry 8 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,748 shares Expires 2027-06-20 F4 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F4 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document
October 01, 2020 Filed Oct 1, 2020 16:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerStock Option (Right to Buy) · Derivative	3,137	Not disclosed Strike: $31.87	Not disclosed	Disclosure SEC source: 0001179110-20-010051 · edgar.xml · derivative · entry 7 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,137 shares Expires 2030-02-07 F4 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F4 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document
October 01, 2020 Filed Oct 1, 2020 16:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerStock Option (Right to Buy) · Derivative	15,674	Not disclosed Strike: $12.76	Not disclosed	Disclosure SEC source: 0001179110-20-010051 · edgar.xml · derivative · entry 6 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,674 shares Expires 2029-02-11 F4 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F4 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document
October 01, 2020 Filed Oct 1, 2020 16:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerStock Option (Right to Buy) · Derivative	23,252	Not disclosed Strike: $17.20	Not disclosed	Disclosure SEC source: 0001179110-20-010051 · edgar.xml · derivative · entry 5 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,252 shares Expires 2027-06-20 F4 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. F4 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option. Read SEC document
October 01, 2020 Filed Oct 1, 2020 16:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerRestricted Stock Units · Derivative	52,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-010051 · edgar.xml · derivative · entry 4 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,500 shares Expires not disclosed F3 · derivative.exercise_price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F3 · price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F3 · derivative.exercise_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F3 · derivative.expiration_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. Read SEC document
October 01, 2020 Filed Oct 1, 2020 16:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerRestricted Stock Unit · Derivative	31,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-010051 · edgar.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,500 shares Expires not disclosed F3 · derivative.exercise_price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F3 · price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F3 · derivative.exercise_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F3 · derivative.expiration_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. Read SEC document
October 01, 2020 Filed Oct 1, 2020 16:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerRestricted Stock Units · Derivative	45,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-010051 · edgar.xml · derivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires not disclosed F3 · derivative.exercise_price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F3 · price: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F3 · derivative.exercise_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. F3 · derivative.expiration_date: Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price. Read SEC document
October 01, 2020 Filed Oct 1, 2020 16:56 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerCommon Stock	26	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-010051 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 26 shares acquired under the Issuer's employee stock purchase plan on September 28, 2020. F2 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. Read SEC document
August 05, 2020 Filed Aug 6, 2020 16:19 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	94	$32.65	$3,069.10	Disclosure SEC source: 0001179110-20-008770 · edgar.xml · nonDerivative · entry 4 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $32.51 to $32.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
August 04, 2020 Filed Aug 6, 2020 16:19 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $17.20	$0.00	Disclosure SEC source: 0001179110-20-008770 · edgar.xml · derivative · entry 6 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,748 Underlying: Common Stock · 22,500 shares Expires 2027-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
August 04, 2020 Filed Aug 6, 2020 16:19 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	10,156	$0.00 Strike: $12.76	$0.00	Disclosure SEC source: 0001179110-20-008770 · edgar.xml · derivative · entry 5 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,702 Underlying: Common Stock · 10,156 shares Expires 2029-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
August 04, 2020 Filed Aug 6, 2020 16:19 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	34,542	$32.25	$1,113,979.50	Disclosure SEC source: 0001179110-20-008770 · edgar.xml · nonDerivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $31.34 to $32.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
August 04, 2020 Filed Aug 6, 2020 16:19 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	22,500	$17.20	$387,000.00	Disclosure SEC source: 0001179110-20-008770 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
August 04, 2020 Filed Aug 6, 2020 16:19 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	10,156	$12.76	$129,590.56	Disclosure SEC source: 0001179110-20-008770 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: Includes 94 shares acquired under the issuer's employee stock purchase plan at a price of $24.98 per share on July 31, 2020 Read SEC document
July 29, 2020 Filed Jul 30, 2020 19:29 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $17.20	$0.00	Disclosure SEC source: 0001179110-20-008594 · edgar.xml · derivative · entry 5 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,248 Underlying: Common Stock · 22,500 shares Expires 2027-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 29, 2020 Filed Jul 30, 2020 19:29 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	10,156	$0.00 Strike: $12.76	$0.00	Disclosure SEC source: 0001179110-20-008594 · edgar.xml · derivative · entry 4 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,858 Underlying: Common Stock · 10,156 shares Expires 2029-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 29, 2020 Filed Jul 30, 2020 19:29 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	39,618	$30.00	$1,188,540.00	Disclosure SEC source: 0001179110-20-008594 · edgar.xml · nonDerivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 29, 2020 Filed Jul 30, 2020 19:29 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	22,500	$17.20	$387,000.00	Disclosure SEC source: 0001179110-20-008594 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 29, 2020 Filed Jul 30, 2020 19:29 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	10,156	$12.76	$129,590.56	Disclosure SEC source: 0001179110-20-008594 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 28, 2020 Filed Jul 28, 2020 17:24 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	681	$30.00	$20,430.00	Disclosure SEC source: 0001179110-20-008529 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,848 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 22, 2020 Filed Jul 23, 2020 16:07 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	1,939	$32.32	$62,668.48	Disclosure SEC source: 0001179110-20-008422 · edgar.xml · nonDerivative · entry 4 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,529 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $31.33 to $34.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
July 21, 2020 Filed Jul 23, 2020 16:07 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $17.20	$0.00	Disclosure SEC source: 0001179110-20-008422 · edgar.xml · derivative · entry 6 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,748 Underlying: Common Stock · 22,500 shares Expires 2027-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 21, 2020 Filed Jul 23, 2020 16:07 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	10,156	$0.00 Strike: $12.76	$0.00	Disclosure SEC source: 0001179110-20-008422 · edgar.xml · derivative · entry 5 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,014 Underlying: Common Stock · 10,156 shares Expires 2029-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 21, 2020 Filed Jul 23, 2020 16:07 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	49,967	$34.62	$1,729,857.54	Disclosure SEC source: 0001179110-20-008422 · edgar.xml · nonDerivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,468 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.23 to $35.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
July 21, 2020 Filed Jul 23, 2020 16:07 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantCommon Stock	22,500	$17.20	$387,000.00	Disclosure SEC source: 0001179110-20-008422 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,435 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 21, 2020 Filed Jul 23, 2020 16:07 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantCommon Stock	10,156	$12.76	$129,590.56	Disclosure SEC source: 0001179110-20-008422 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,935 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 20, 2020 Filed Jul 21, 2020 16:03 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	1,561	$33.95	$52,995.95	Disclosure SEC source: 0001179110-20-008397 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,779 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 17, 2020 Filed Jul 21, 2020 16:03 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionRestricted Stock Units · Derivative	3,500	$0.00	$0.00	Disclosure SEC source: 0001179110-20-008397 · edgar.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F4 · derivative.exercise_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. F4 · derivative.expiration_date: Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 25% of the shares on the first anniversary of the grant date, and the remainder will vest in equal quarterly installments over the subsequent three years. Read SEC document
July 17, 2020 Filed Jul 21, 2020 16:03 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionCommon Stock	3,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-008397 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares received pursuant to settlement of Restricted Stock Units that were granted on October 17, 2018. F3 · price: Restricted Stock Units convert into common stock on a one-for-one basis. Read SEC document
July 15, 2020 Filed Jul 16, 2020 16:28 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $17.20	$0.00	Disclosure SEC source: 0001179110-20-008284 · edgar.xml · derivative · entry 6 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,248 Underlying: Common Stock · 22,500 shares Expires 2027-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 15, 2020 Filed Jul 16, 2020 16:28 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Exercise / conversionStock Option (Right to Buy) · Derivative	10,156	$0.00 Strike: $12.76	$0.00	Disclosure SEC source: 0001179110-20-008284 · edgar.xml · derivative · entry 5 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,170 Underlying: Common Stock · 10,156 shares Expires 2029-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 15, 2020 Filed Jul 16, 2020 16:28 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	16,433	$35.35	$580,906.55	Disclosure SEC source: 0001179110-20-008284 · edgar.xml · nonDerivative · entry 4 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,840 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $34.82 to $36.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
July 15, 2020 Filed Jul 16, 2020 16:28 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	34,921	$35.35	$1,234,457.35	Disclosure SEC source: 0001179110-20-008284 · edgar.xml · nonDerivative · entry 3 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,273 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.78 to $36.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
July 15, 2020 Filed Jul 16, 2020 16:28 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantCommon Stock	22,500	$17.20	$387,000.00	Disclosure SEC source: 0001179110-20-008284 · edgar.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,194 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
July 15, 2020 Filed Jul 16, 2020 16:28 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	GrantCommon Stock	10,156	$12.76	$129,590.56	Disclosure SEC source: 0001179110-20-008284 · edgar.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,694 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
June 30, 2020 Filed Jul 1, 2020 21:15 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	SaleCommon Stock	6,812	$35.10	$239,101.20	Disclosure SEC source: 0001104659-20-080021 · a4.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,538 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.